Chimeric antigen receptor (CAR) T-cell therapy offers a potentially curative option for patients with relapsed and refractory hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL).

Patient-reported experiences with CAR T therapy are limited and have not been well characterized.

The purpose of this qualitative study was to explore patient descriptions of key domains of health-related quality of life in DLBCL patients treated with CAR T therapy.

The use of patient-reported outcomes (PRO) measures, specifically key domains identified in the study, may help clinicians better understand the patient needs for this disease state and reinforce therapeutic approaches.

PROs provide qualitative information on different aspects of their disease before, during, and after treatment to track their journey.

These data can be used to help inform programs that may provide better support to DLBCL patients and caregivers.